The recent approval of Zepbound, a weight loss drug, for the treatment of obstructive sleep apnea in obese adults, has sparked a debate about the potential financial implications for plan sponsors. While this development offers a new treatment option, it also raises concerns about cost-effectiveness and the long-term financial sustainability of benefits plans.
The Double-Edged Sword of Zepbound
Zepbound's approval as a treatment for sleep apnea is a significant step forward for a specific group of plan members. However, it's important to note that this medication is not a broad replacement for the widely used and cost-effective Continuous Positive Airway Pressure (CPAP) machines. CPAP therapy remains the first-line treatment for most employees diagnosed with obstructive sleep apnea, and its immediate effectiveness and lower total cost make it a preferred choice.
Financial Risks and Cost-Effectiveness
Even with the consideration of maintenance and supply costs, the total cost of treating sleep apnea with CPAP machines is significantly lower than the drug costs associated with Zepbound. This disparity in costs is a crucial factor that plan sponsors must consider to minimize financial risks.
A Narrow Indication, a Broad Impact
Joseph Koo, Assistant Vice-President of Health Solutions and National Pharmacist at Aon, emphasizes the need for a cost-effectiveness lens when considering Zepbound's expanded treatment indication. He warns that a narrow indication for sleep apnea should not become the gateway to broad and permanent coverage of glucagon-like peptide-1 (GLP-1) therapies, which were initially intended for weight management.
Clear criteria, such as a documented sleep study, body mass index thresholds, and the requirement to try CPAP therapy first, are essential to control costs and ensure appropriate use of Zepbound. These criteria, along with prior authorization and periodic reassessments, are crucial given the indefinite nature of these therapies and their perpetual financial impact on plans.
The Challenge of Expanded Indications
One of the challenges plan sponsors face is the current technology at the pharmacy benefit manager or carrier level, which does not effectively control costs based on indication. Each new indication for a drug, like Zepbound, opens another door into the formulary, potentially leading to increased costs for plan sponsors.
A Broader Perspective
The approval of Zepbound for sleep apnea treatment highlights the delicate balance between providing innovative treatments and managing the financial sustainability of benefits plans. As we navigate this complex landscape, it's crucial to consider the long-term implications of expanded indications and the potential impact on plan sponsors and employees alike. This case also underscores the need for ongoing dialogue and collaboration between healthcare providers, plan sponsors, and technology providers to ensure cost-effective and sustainable healthcare solutions.
